Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.
Saved in:
| Title: | Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. |
|---|---|
| Authors: | Qualls D; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Noy A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Straus D; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Matasar M; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Moskowitz C; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Seshan V; Department of Epidemiology and Biostatistics, Biostatistics Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Dogan A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Salles G; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Younes A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Zelenetz AD; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Batlevi CL; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USA. |
| Source: | Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 738-741. Date of Electronic Publication: 2023 Jan 15. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
